Millendo Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
M&A
- Financing Rounds
-
7
- Investments
-
3
Millendo Therapeutics General Information
Description
Developer of novel drugs designed for the treatment of endocrine diseases caused by hormone dysregulation. The company pursues distinct and transformative treatments and leverage scientific advances to develop novel compounds to treat complex conditions and advance clinical care, enabling patients, families, and caregivers to live fuller lives.
Contact Information
Website
www.millendo.comCorporate Office
- 110 Miller Avenue
- Suite 100
- Ann Arbor, MI 48104
- United States
Corporate Office
- 110 Miller Avenue
- Suite 100
- Ann Arbor, MI 48104
- United States
Millendo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Millendo Therapeutics Comparisons
Industry
Financing
Details
Millendo Therapeutics Competitors (4)
One of Millendo Therapeutics’s 4 competitors is CSL Behring, a Corporation company based in King Of Prussia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CSL Behring | Corporation | King Of Prussia, PA | ||||
| CSL Behring (Biotechnology) | Corporation | Vienna, Austria | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Kedrion | Private Equity-Backed | Barga, Italy |
Millendo Therapeutics Patents
Millendo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021030335-A1 | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof | Inactive | 12-Aug-2019 | ||
| WO-2017011302-A1 | Enhanced bioavailability of n-(2,6-bis(1-methylethyl) phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl) methyl)urea hydrochloride | Inactive | 10-Jul-2015 | ||
| WO-2016164476-A3 | Combination of an acat1 inhibitor and a cyp1 1 b1 inhibitor for treating disorders associated with excess cortisol production | Inactive | 06-Apr-2015 | ||
| US-20160287565-A1 | Combination therapy for treating disorders associated with excess cortisol production | Inactive | 06-Apr-2015 | ||
| WO-2016164476-A2 | Combination therapy for treating disorders associated with excess cortisol production | Inactive | 06-Apr-2015 | A61K31/444 |
Millendo Therapeutics Signals
Millendo Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Millendo Therapeutics Acquisitions (3)
Millendo Therapeutics’s most recent deal was a Reverse Merger with Tempest Therapeutics. The deal was made on 28-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tempest Therapeutics | 28-Jun-2021 | Reverse Merger | Drug Discovery | ||
| OvaScience | 07-Dec-2018 | Merger/Acquisition | Biotechnology | ||
| Alizé Pharma | 20-Dec-2017 | Merger/Acquisition | Pharmaceuticals |
Millendo Therapeutics Exits (1)
Millendo Therapeutics’s most recent exit was on 28-Jun-2021 from Tempest Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Tempest Therapeutics | 28-Jun-2021 | Completed |
|
Millendo Therapeutics FAQs
-
When was Millendo Therapeutics founded?
Millendo Therapeutics was founded in 2011.
-
Where is Millendo Therapeutics headquartered?
Millendo Therapeutics is headquartered in Ann Arbor, MI.
-
What is the size of Millendo Therapeutics?
Millendo Therapeutics has 7 total employees.
-
What industry is Millendo Therapeutics in?
Millendo Therapeutics’s primary industry is Biotechnology.
-
Is Millendo Therapeutics a private or public company?
Millendo Therapeutics is a Private company.
-
What is Millendo Therapeutics’s current revenue?
The current revenue for Millendo Therapeutics is .
-
How much funding has Millendo Therapeutics raised over time?
Millendo Therapeutics has raised $131M.
-
Who are Millendo Therapeutics’s investors?
5AM Ventures, Adams Street Partners, Altitude Life Science Ventures, Ann Arbor SPARK, and AstraZeneca are 5 of 18 investors who have invested in Millendo Therapeutics.
-
Who are Millendo Therapeutics’s competitors?
CSL Behring, CSL Behring (Biotechnology), Genetix Biotherapeutics, and Kedrion are competitors of Millendo Therapeutics.
-
When was Millendo Therapeutics acquired?
Millendo Therapeutics was acquired on 25-Jun-2021.
-
Who acquired Millendo Therapeutics?
Millendo Therapeutics was acquired by Tempest Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process